These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 30076293)

  • 1. Systemic and mucosal humoral immune responses induced by the JY-adjuvanted nasal spray H7N9 vaccine in mice.
    Xu J; Li S; Wang X; Liu J; Shan P; Zhou Y; Zhao J; Wang Z; Xu C; Chen M; Chen Z; Zhao K; Qu D
    Emerg Microbes Infect; 2018 Aug; 7(1):140. PubMed ID: 30076293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-lasting protective immunity against H7N9 infection is induced by intramuscular or CpG-adjuvanted intranasal immunization with the split H7N9 vaccine.
    Zhou Y; Li S; Bi S; Li N; Bi Y; Liu W; Wang B
    Int Immunopharmacol; 2020 Jan; 78():106013. PubMed ID: 31806571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plant-derived H7 VLP vaccine elicits protective immune response against H7N9 influenza virus in mice and ferrets.
    Pillet S; Racine T; Nfon C; Di Lenardo TZ; Babiuk S; Ward BJ; Kobinger GP; Landry N
    Vaccine; 2015 Nov; 33(46):6282-9. PubMed ID: 26432915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial.
    Jackson LA; Campbell JD; Frey SE; Edwards KM; Keitel WA; Kotloff KL; Berry AA; Graham I; Atmar RL; Creech CB; Thomsen IP; Patel SM; Gutierrez AF; Anderson EL; El Sahly HM; Hill H; Noah DL; Bellamy AR
    JAMA; 2015 Jul; 314(3):237-46. PubMed ID: 26197184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Squalene-adjuvanted H7N9 virus vaccine induces robust humoral immune response against H7N9 and H7N7 viruses.
    Wu CY; Chang CY; Ma HH; Wang CW; Chen YT; Hsiao PW; Chang CC; Chan CH; Liu CC; Chen JR
    Vaccine; 2014 Jul; 32(35):4485-4494. PubMed ID: 24962757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new adjuvanted nanoparticle-based H1N1 influenza vaccine induced antigen-specific local mucosal and systemic immune responses after administration into the lung.
    Neuhaus V; Chichester JA; Ebensen T; Schwarz K; Hartman CE; Shoji Y; Guzmán CA; Yusibov V; Sewald K; Braun A
    Vaccine; 2014 May; 32(26):3216-22. PubMed ID: 24731807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults.
    Madan A; Segall N; Ferguson M; Frenette L; Kroll R; Friel D; Soni J; Li P; Innis BL; Schuind A
    J Infect Dis; 2016 Dec; 214(11):1717-1727. PubMed ID: 27609809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocine™, N3OA and N3OASq; three mucosal adjuvants that enhance the immune response to nasal influenza vaccination.
    Falkeborn T; Bråve A; Larsson M; Akerlind B; Schröder U; Hinkula J
    PLoS One; 2013; 8(8):e70527. PubMed ID: 23950951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of an inactivated cell culture-derived H7N9 influenza vaccine in healthy adults: A phase I/II, prospective, randomized, open-label trial.
    Wu UI; Hsieh SM; Lee WS; Wang NC; Kung HC; Ou TY; Chen FL; Lin TY; Chen YC; Chang SC
    Vaccine; 2017 Jul; 35(33):4099-4104. PubMed ID: 28668573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single immunization with MF59-adjuvanted inactivated whole-virion H7N9 influenza vaccine provides early protection against H7N9 virus challenge in mice.
    Chang H; Duan J; Zhou P; Su L; Zheng D; Zhang F; Fang F; Li X; Chen Z
    Microbes Infect; 2017 Dec; 19(12):616-625. PubMed ID: 28899814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-protective efficacy of baculovirus displayed hemagglutinin against highly pathogenic influenza H7 subtypes.
    Prabakaran M; Kumar SR; Raj KV; Wu X; He F; Zhou J; Kwang J
    Antiviral Res; 2014 Sep; 109():149-59. PubMed ID: 24997413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age.
    Poder A; Simurka P; Li P; Roy-Ghanta S; Vaughn D
    Vaccine; 2014 Feb; 32(9):1121-9. PubMed ID: 24252703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Divergent H7 immunogens offer protection from H7N9 virus challenge.
    Krammer F; Albrecht RA; Tan GS; Margine I; Hai R; Schmolke M; Runstadler J; Andrews SF; Wilson PC; Cox RJ; Treanor JJ; García-Sastre A; Palese P
    J Virol; 2014 Apr; 88(8):3976-85. PubMed ID: 24453375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ISCOMATRIX™ adjuvant promotes epitope spreading and antibody affinity maturation of influenza A H7N9 virus like particle vaccine that correlate with virus neutralization in humans.
    Chung KY; Coyle EM; Jani D; King LR; Bhardwaj R; Fries L; Smith G; Glenn G; Golding H; Khurana S
    Vaccine; 2015 Jul; 33(32):3953-62. PubMed ID: 26093202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A synthetic TLR4 agonist significantly increases humoral immune responses and the protective ability of an MDCK-cell-derived inactivated H7N9 vaccine in mice.
    Luo J; Zhang M; Ye Q; Gao F; Xu W; Li B; Wang Q; Zhao L; Tan WS
    Arch Virol; 2024 Jul; 169(8):163. PubMed ID: 38990396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of varying dosages of a fifth-wave influenza A/H7N9 inactivated vaccine given with and without AS03 adjuvant in healthy adults.
    Jackson LA; Stapleton JT; Walter EB; Chen WH; Rouphael NG; Anderson EJ; Neuzil KM; Winokur PL; Smith MJ; Schmader KE; Swamy GK; Thompson AB; Mulligan MJ; Rostad CA; Cross K; Tsong R; Wegel A; Roberts PC
    Vaccine; 2024 Jan; 42(2):295-309. PubMed ID: 38105137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of Humoral Responses Induced by an H7N9 Influenza Virus-Like Particle Vaccine in BALB/C Mice.
    Zhang L; Lu J; Chen Y; Shi F; Yu H; Huang C; Cui L; Shi Z; Jiao Y; Hu Y
    Viruses; 2015 Aug; 7(8):4369-84. PubMed ID: 26248076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant influenza A virus hemagglutinin HA2 subunit protects mice against influenza A(H7N9) virus infection.
    To KK; Zhang AJ; Chan AS; Li C; Cai JP; Lau CC; Li CG; Jahan AS; Wu WL; Li L; Tsang AK; Chan KH; Chen H; Yuen KY
    Arch Virol; 2015 Mar; 160(3):777-86. PubMed ID: 25616843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A recombinant H7N9 influenza vaccine with the H7 hemagglutinin transmembrane domain replaced by the H3 domain induces increased cross-reactive antibodies and improved interclade protection in mice.
    Wang Y; Wu J; Xue C; Wu Z; Lin Y; Wei Y; Wei X; Qin J; Zhang Y; Wen Z; Chen L; Liu GD; Cao Y
    Antiviral Res; 2017 Jul; 143():97-105. PubMed ID: 28408133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunopotentiation of Different Adjuvants on Humoral and Cellular Immune Responses Induced by HA1-2 Subunit Vaccines of H7N9 Influenza in Mice.
    Song L; Xiong D; Hu M; Kang X; Pan Z; Jiao X
    PLoS One; 2016; 11(3):e0150678. PubMed ID: 26930068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.